melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
C-Jun drives melanoma progression in PTEN wild type melanoma cells.
|
31378787 |
2019 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We also evaluated the antitumor activity of an anti-OX40 antibody plus PI3Kβ inhibition in a transgenic murine melanoma model (<i>Braf</i> mutant, PTEN null), which spontaneously develops immunotherapy-resistant melanomas.
|
31371342 |
2019 |
melanoma
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
Somatic oncogenic mutation of BRAF coupled with inactivation of PTEN constitute a frequent combination of genomic alterations driving the development of human melanoma.
|
31065107 |
2020 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells.
|
30863489 |
2019 |
melanoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The dCas9-VPR system increased PTEN expression in melanoma and TNBC cell lines, without transcriptional regulation at predicted off-target sgRNA binding sites.
|
30654190 |
2019 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PTEN immunohistochemical loss, a common event in endometrioid-type endometrial carcinoma and associated with local immune suppression in melanoma, was not associated with PD-L1 expression or lymphocyte/macrophage infiltration of the tumor.
|
30291344 |
2019 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
MiR-637 suppresses melanoma progression through directly targeting P-REX2a and inhibiting PTEN/AKT signaling pathway.
|
30213289 |
2018 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of somatic mutations in BRAF (96%) and PTEN (36%) in the AYA WGS cohort were double the rates observed in adult melanomas (Q < 6.0 × 10<sup>-6</sup> and 0.028, respectively).
|
30178487 |
2019 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PTEN genomic alterations (deletion, mutation), promoter methylation, and protein destabilization did not fully explain PTEN loss in melanoma, whereas PTEN levels increased with treatment of melanoma cells with the histone deacetylase inhibitor LBH589.
|
30148988 |
2019 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The metformin/sitagliptin combination was effective in a BRAFV600E/PTEN tamoxifen-inducible murine melanoma model.
|
29899823 |
2018 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We observe selection for low-abundance PTEN variants in cancer, and show that p.Pro38Ser, which accounts for ~10% of PTEN missense variants in melanoma, functions via a dominant-negative mechanism.
|
29785012 |
2018 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
<i>PHIP</i> copy number was enriched in metastatic melanomas harboring mutant <i>NRAS</i> or expressing PTEN protein (cohort No.2).
|
29776954 |
2018 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Functional and genomic analyses of patient-derived melanomas revealed that PTEN loss is associated with NHEJ deficiency.
|
29739874 |
2018 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Moreover, we identified AXL as a key upstream effector of AKT pathway-associated resistance to BRAFi in melanoma with wildtype PTEN, but not in melanoma with impaired PTEN.
|
29551771 |
2018 |
melanoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-331 suppressed the activation of the PTEN/AKT signalling pathway in melanoma by inhibiting AEG-1.
|
29510779 |
2018 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Suppression of MAPK signaling in BRAF-activated PTEN-deficient melanoma by blocking β-catenin signaling in cancer-associated fibroblasts.
|
29045061 |
2018 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Treatment with ST-162 produced regression of mutant KRAS- or BRAF-addicted xenograft models of colorectal cancer and melanoma and stasis of BRAF/PTEN-mutant melanomas.
|
28775144 |
2017 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Additionally, p62 forms a feedback loop with PTEN in melanoma cells, suggesting p62 functions as an oncogene in UVA-associated melanoma development and progression.
|
28715145 |
2018 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Co-treatment of phenformin enhances the effect of anti-PD-1 antibody therapy on inhibiting tumor growth in the BRAF V600E/PTEN-null melanoma mouse model.
|
28433543 |
2017 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, these data not only provide mechanistic insight into Abl/Arg regulation during melanoma development, but also pave the way for the development of new strategies for treating patients with melanomas harboring mutant BRAF/PTEN, which often are refractory to current therapies.
|
28368422 |
2017 |
melanoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
It was also observed that the Akt and FAK signaling pathways were involved in miR-301/PTEN-promoting MM progression.
|
27855389 |
2016 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that concurrent loss of PTEN and activation of the Notch pathway is associated with poor response to the ERK inhibitor SCH772984, and that co-inhibition of Notch and ERK decreased viability in BRAF-V600E melanomas.
|
27655717 |
2016 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that SAR260301 blocks PI3K pathway signaling preferentially in PTEN-deficient human tumor models, and has synergistic antitumor activity when combined with vemurafenib (BRAF inhibitor) or selumetinib (MEK inhibitor) in PTEN-deficient/BRAF-mutated human melanoma tumor models.
|
27196754 |
2016 |
melanoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
PREX2 (phosphatidylinositol-3,4,5-triphosphate-dependent Rac-exchange factor 2) is a PTEN (phosphatase and tensin homolog deleted on chromosome 10) binding protein that is significantly mutated in cutaneous melanoma and pancreatic ductal adenocarcinoma.
|
26884185 |
2016 |
melanoma
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
We thus sought to elucidate the prevalence of PTEN promoter methylation in melanoma specimens, its relationship to clinical features, and its impact on the outcome of patients with melanoma.
|
26854490 |
2016 |